PDF(Pubmed)
Abstract：
To evaluate and compare the efficacy of autologous platelet-rich plasma (aPRP) eye drop and artificial tear (AT) eye drop in moderate to severe symptomatic dry eye disease (DED).
This prospective interventional study included 121 eyes of 61 patients of moderate to severe DED. Patients were divided into aPRP (31 patients) and AT (30 patients) group. Ocular Surface Disease Index (OSDI) score, tear film breakup time (TBUT) (s), corneal fluorescein staining (CFS) score, and Schirmer test score (mm) of both the groups were evaluated and compared pre-treatment and post-treatment at the end of 3 months.
The mean age of the aPRP group and AT group was 52.8 ± 12.8 years and 55.5 ± 13.4 years, respectively. At the end of 3 months, OSDI score reduced more in the aPRP group as compared to AT group, and the mean difference (-22.7) was statistically significant (P < 0.001). There was no significant difference in post-treatment Schirmer test score between the two groups (P = 0.44). Post-treatment improvement in TBUT and CFS score in the aPRP group was significantly higher in the aPRP group as compared to that in the AT group (P < 0.05). Bruising at the site of blood withdrawal was noted in two patients in the aPRP group.
aPRP is safe and more effective than AT in treating patients with moderate to severe symptomatic DED.
This prospective interventional study included 121 eyes of 61 patients of moderate to severe DED. Patients were divided into aPRP (31 patients) and AT (30 patients) group. Ocular Surface Disease Index (OSDI) score, tear film breakup time (TBUT) (s), corneal fluorescein staining (CFS) score, and Schirmer test score (mm) of both the groups were evaluated and compared pre-treatment and post-treatment at the end of 3 months.
The mean age of the aPRP group and AT group was 52.8 ± 12.8 years and 55.5 ± 13.4 years, respectively. At the end of 3 months, OSDI score reduced more in the aPRP group as compared to AT group, and the mean difference (-22.7) was statistically significant (P < 0.001). There was no significant difference in post-treatment Schirmer test score between the two groups (P = 0.44). Post-treatment improvement in TBUT and CFS score in the aPRP group was significantly higher in the aPRP group as compared to that in the AT group (P < 0.05). Bruising at the site of blood withdrawal was noted in two patients in the aPRP group.
aPRP is safe and more effective than AT in treating patients with moderate to severe symptomatic DED.
摘要：
评价和比较自体富血小板血浆(aPRP)滴眼液与人工泪液(AT)滴眼液治疗中重度症状性干眼症(DED)的疗效。
这项前瞻性介入研究包括61例中度至重度DED患者的121只眼。患者分为aPRP组(31例)和AT组(30例)。眼表疾病指数（OSDI）评分，泪膜破裂时间(TBUT)角膜荧光素染色（CFS）评分，在治疗前和治疗后3个月时对两组的Schirmer测试评分（mm）进行评估和比较。
aPRP组和AT组的平均年龄分别为52.8±12.8岁和55.5±13.4岁,分别。在三个月结束时，与AT组相比，aPRP组OSDI评分降低更多，平均差异（-22.7）有统计学意义（P<0.001）。两组治疗后Schirmer检验评分差异无统计学意义(P=0.44)。aPRP组治疗后TBUT和CFS评分改善明显高于AT组(P<0.05)。在aPRP组中的两名患者中注意到抽血部位的瘀伤。
aPRP在治疗中度至重度症状性DED患者方面安全且比AT更有效。
这项前瞻性介入研究包括61例中度至重度DED患者的121只眼。患者分为aPRP组(31例)和AT组(30例)。眼表疾病指数（OSDI）评分，泪膜破裂时间(TBUT)角膜荧光素染色（CFS）评分，在治疗前和治疗后3个月时对两组的Schirmer测试评分（mm）进行评估和比较。
aPRP组和AT组的平均年龄分别为52.8±12.8岁和55.5±13.4岁,分别。在三个月结束时，与AT组相比，aPRP组OSDI评分降低更多，平均差异（-22.7）有统计学意义（P<0.001）。两组治疗后Schirmer检验评分差异无统计学意义(P=0.44)。aPRP组治疗后TBUT和CFS评分改善明显高于AT组(P<0.05)。在aPRP组中的两名患者中注意到抽血部位的瘀伤。
aPRP在治疗中度至重度症状性DED患者方面安全且比AT更有效。
